r112

R112 是 ATP 竞争性的 Syk 激酶抑制剂，它能够抑制 Syk 激酶活性，Ki=6 nM，IC50=226 nM。

DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂，对 EGFRWT 和 EGFRL858R T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。

SR11237 是一种泛视黄醇 X 受体 (RXR) 激动剂。 SR11237 导致 RXR RXR 同源二聚体形成并反式激活包含 RXR 反应元件的报告基因。

DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112 not only displayed a potent inhibitory activity against EGFRL858R T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models.

(12aR)-1,12-Bis(diphenylphosphino)-6,7-dihydrodibenzo[e,g][1,4]dioxocine 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T67395。

Berupipam is a dopamine D1 receptor antagonist.

GR-112000 is a peptide-based tachykinin NK2 receptor antagonist.